2023-01-27 08:30ZICCUM AB (publ) Year-end report Q4 2022
YEAR-END REPORT Q4 2022: 1 JANUARY – 31 DECEMBER 2022 To read the digital Report, please click here: https://reports-en.ziccum.com/year-end-report-q4-2022/start/ Significant events in Q4 (October - December) On October 24, Ziccum announced proof...
2023-01-23 15:07Ziccum submits Expression of Interest for CEPI funding
Ziccum AB (publ) (‘Ziccum’) has now submitted its Expression of Interest application for CEPI’s Call for Proposals for funding of innovations that improve vaccine thermostability. The Coalition for Epidemic Preparedness (CEPI), in 2022...
2023-01-18 12:30Ziccum CEO to present at international mRNA Summit in Berlin
Lund, Jan 18, 2023 —Ziccum AB CEO Ann Gidner will present LaminarPace, the company’s unique mass transfer drying methodology, at the mRNA-based Therapeutics Summit in Berlin 24 – 26 January. It is the leading European event for mRNA...
Ziccum AB has been awarded non-dilutive funding of 10 MSEK by Eurostars for a joint application with the Institute of Computational Physics (ICP) at the School of Engineering at Zurich University of Applied Sciences (ZHAW). The project (application #...
2022-12-14 16:16Ziccum launches new, expanded website
Lund, Nov 14, 2022 —Ziccum AB (publ) (‘Ziccum’) has launched a new website, developed in partnership with the Chords Agency in Malmö. With a new brand platform, the expanded site aims to strengthen the company’s dialogue with...
2022-12-08 09:25Ziccum signs agreement with Zurich University of Applied Sciences on advanced 3D-modeling project
Ziccum AB has signed an agreement contracting the ICP Institute of Computational Physics at the Zurich University of Applied Sciences’ School of Engineering (ZHAW) for the next phase of the project developing 3D modelling of LaminarPace - Ziccum’s...
2022-10-28 16:50Ziccums Q3-resultat: VD-uppdatering på svenska
Ziccum har haft ett mycket produktivt kvartal, med avsevärda framsteg inom de tre fokusområdena: Partnering, Teknologiutveckling och Förstudien för mRA/LNP-plattformen. Ann Gidner, Ziccums nya VD som tillträdde i maj månad...
2022-10-27 08:30ZICCUM AB (publ) Interim report Q3 2022
INTERIM REPORT Q3 2022: 1 JANUARY – 30 SEPTEMBER 2022. To read the digital Report, please click here: https://reports-en.ziccum.com/interim-report-q3-2022/start/ Significant events during Q3 (July-September) On July 19, Ziccum published the selected...
ZICCUM AB (publ) has generated proof of successful nebulization and drying of vaccine lipid nanoparticles (LNP) in its in-house mRNA project. This was carried out using LaminarPaceTM, the company’s ambient drying technology. LNP is the preferred...
2022-09-27 08:30Ziccum reopens application for CEPI funding on thermostable vaccines with new partner
Ziccum AB (publ) (‘Ziccum’) today announces that is has reopened its application process for CEPI’s Call for Proposals (CfP) from companies developing innovative technologies to improve vaccine thermostability. Ziccum will submit an...
2022-09-23 15:12Ziccum receives results from evaluation study with leading Pharmaceutical Corporation
Ziccum AB (publ) (‘Ziccum’) has today received readout results from the latest stage of an evaluation agreement study carried out with a leading pharmaceutical corporation (previously communicated on June 3, 2022) analyzing LaminarPace’s...
2022-09-14 15:30Ziccum and Zurich University of Applied Sciences submit joint application for Eurostars funding
Following their agreed collaboration, Ziccum AB and the team from the ICP Institute of Computational Physics at the Zurich University of Applied Sciences’s School of Engineering (ZHAW) have now submitted an application to the Eurostars funding body...
Ziccum AB will be intensifying its partnering and networking dialogues at a series of leading pharma industry events throughout Europe this year. CEO Ann Gidner: “As we strengthen our connections with colleagues throughout the industry, we remain...
2022-08-23 08:30ZICCUM AB (publ) Interim report Q2 2022
INTERIM REPORT Q2 2022: 1 JANUARY – 30 JUNE 2022. To read the digital Report click here: https://reports-en.ziccum.com/interim-report-q2-2022/ Significant events during Q2 (April-June) Significant events during Q1 (Jan-March) With a new CEO, the...
2022-08-02 08:30Ziccum appoints new Scientific Director
Ziccum AB has appointed a Scientific Director, as part of a major reorganisation aiming to facilitate and accelerate its new strategic focus on key projects and vaccine platforms. Ziccum Senior Formulation Specialist Fabrice Rose will assume the new role...
Ziccum AB, in partnership with the prestigious Zurich University of Applied Sciences, is applying for funding to Eurostars for a joint project developing the 3D modelling of LaminarPace, its unique room-temperature drying system that formulates vaccines...
Ziccum has chosen TEKCELEO, an innovative mechatronic manufacturer with advanced knowledge of nebulizers, for the development of its new nebulizer. The component is central to the advanced drying capabilities and scaleup of Ziccum’s LaminarPace...
2022-06-29 11:30Three key learnings as collaboration between Ziccum and Emerging Virus Unit at Aix-Marseille University draws to a close
In Ziccum’s recent major strategy renewal it sharpened its focus onto three key vaccine platforms and streamlined its R&D projects down to three key partnerships. The company is also pleased to now conclude its long-term collaboration with the...
2022-06-22 08:30Ziccum installs new cell lab enabling in-house in vitro research
Lund, June 22, 2022 —Ziccum AB (publ) (‘Ziccum’) has completed the installation of a new cell lab, on schedule, as part of its strategy of intensive technology development. The new cell lab increases the company’s capabilities...
2022-06-17 09:00From vision to action: new Ziccum CEO update
On May 9, 2022, Ann Gidner became new CEO of Ziccum, hitting the ground running with a raft of new strategies that included targeting three key high-potential vaccines, streamlining the company’s project pipeline and strengthening the focus on industrial...